EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

EGFR p. V774M /p. the S768I Compound Mutation in NSCLC Is a Good Prognostic Marker for IPHC ‐ and Furmonertinib‐Based Treatment: A Case Report

Yanan Wang, Guanying Ren, Zizheng Song iD, Ling Hu iD, Weiqi Li, Xiaolei Wang

Cancer Reports · 2026

DOI: 10.1002/cnr2.70444 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cancer Reports, 2026. Verfasst von Yanan Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Affiliated Hospital of Hebei University, Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Baoding, Hebei…. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Science Research Project of Hebei.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Intrapleural perfusion hyperthermic chemotherapy (IPHC) can be used to select specific lung cancer cells of a certain genotype. Some genetic mutations, especially epidermal growth factor receptor (EGFR) mutations, are potential markers for EGFR or other targeted therapies. Here, we report a unique case of a patient with EGFR p.V774M/p. S768I mutations that were associated with prolonged stable disease after treatment with IHPC, especially following furmonertinib‐based treatment. Case A 47‐year‐old Chinese female patient was admitted to a regional cancer hospital and presented with malignant pleural effusion (MPE). The TNM and clinical stages were identified as T2aN2M1c and IVB, respectively. The TPS value is 40%. IHP combined with chemotherapy was then carried out to remove MPE. For first‐stage treatment, three cycles of afatinib‐based adjuvant chemotherapy beginning in September 2022 were given, and the degree of pleural effusion on the left side of the chest was not reduced. The best response (BOR) assessment of the local lesion was a partial response (PR). Furmonertinib‐based adjuvant monotherapy was performed from May 2023 to July 2024. The BOR evaluation results during the monotherapy courses were all judged as SD.

Conclusion

The EGFR p.V774M/p.The S768I mutation contributed to improving the efficiency of furmonertinib‐based therapy for NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoma, Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMiddle AgedErbB ReceptorsMutationPrognosisAfatinibPleural Effusion, MalignantBiomarkers, TumorAnilidesQuinolines

Stichwörter der Autor:innen

EGFRIPHCNSCLCcompound mutationfurmonertinib

Substanzen

ErbB ReceptorsEGFR protein, humanAfatinibGSK 1363089Biomarkers, TumorAnilidesQuinolines

Autor:innen und Institutionen

  • Department of Medical Oncology, Affiliated Hospital of Hebei University, Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Baoding, Hebei, China.

ORCID-Profile: Zizheng Song, Ling Hu

Förderung

  • Medical Science Research Project of Hebei

Zitieren

APA

Wang, Y., Ren, G., Song, Z., Hu, L., Li, W., & Wang, X. (2026). EGFR p. V774M /p. the S768I Compound Mutation in NSCLC Is a Good Prognostic Marker for IPHC ‐ and Furmonertinib‐Based Treatment: A Case Report. Cancer Reports. https://doi.org/10.1002/cnr2.70444

Vancouver

Wang Y, Ren G, Song Z, Hu L, Li W, Wang X. EGFR p. V774M /p. the S768I Compound Mutation in NSCLC Is a Good Prognostic Marker for IPHC ‐ and Furmonertinib‐Based Treatment: A Case Report. Cancer Reports. 2026. doi:10.1002/cnr2.70444

BibTeX
@article{Wang2026,
  author = {Wang, Yanan and Ren, Guanying and Song, Zizheng and Hu, Ling and Li, Weiqi and Wang, Xiaolei},
  title = {EGFR p. V774M /p. the S768I Compound Mutation in NSCLC Is a Good Prognostic Marker for IPHC ‐ and Furmonertinib‐Based Treatment: A Case Report},
  journal = {Cancer Reports},
  year = {2026},
  doi = {10.1002/cnr2.70444}
}
Kostenlos starten →